

James E Talmadge

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5424444/publications.pdf>

Version: 2024-02-01

180
papers

7,624
citations

125106

35
h-index

62345

84
g-index

191
all docs

191
docs citations

191
times ranked

12473
citing authors

#	ARTICLE	IF	CITATIONS
1	Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients. <i>International Immunopharmacology</i> , 2022, 106, 108628.	1.7	1
2	Role of myeloid-derived suppressor cells in metastasis. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 391-411.	2.7	22
3	Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis. <i>Cellular Immunology</i> , 2021, 363, 104317.	1.4	13
4	Preface. <i>Cancer and Metastasis Reviews</i> , 2021, 40, 983-984.	2.7	0
5	Myeloid derived suppressor cells and the release of micro-metastases from dormancy. <i>Clinical and Experimental Metastasis</i> , 2021, 38, 279-293.	1.7	6
6	Covid-19 challenges to immune investigations and therapies. <i>International Immunopharmacology</i> , 2021, 95, 107543.	1.7	1
7	Abstract 3153: Targeting the stress response kinase GCN2 to restore immunity in the tumor microenvironment. , 2021, , .		0
8	Antimicrobial efficacy of aqueous ozone in combination with short chain fatty acid buffers. <i>Infection Prevention in Practice</i> , 2020, 2, 100032.	0.6	8
9	Comparative phenotypes of peripheral blood and spleen cells from cancer patients. <i>International Immunopharmacology</i> , 2020, 85, 106655.	1.7	4
10	Quantity does not equal quality: Scientific principles cannot be sacrificed. <i>International Immunopharmacology</i> , 2020, 86, 106711.	1.7	52
11	A discussion on considerations in scientific integrity. <i>International Immunopharmacology</i> , 2020, 81, 106332.	1.7	0
12	Fatty Acid Mediators in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1259, 125-153.	0.8	9
13	Mitigation of microbial contamination from waste water and aerosolization by sink design. <i>Journal of Hospital Infection</i> , 2019, 103, 193-199.	1.4	6
14	Abstract 1420: Novel expansion of CD8+PD1+ spleen cells for therapeutic intent in pancreatic adenocarcinoma cancer. , 2019, , .		0
15	Abstract 4049: Cellular phenotypes of spleen cells in cancer patients targeted for adoptive cellular therapy. , 2019, , .		0
16	Abstract 1420: Novel expansion of CD8+PD1+ spleen cells for therapeutic intent in pancreatic adenocarcinoma cancer. , 2019, , .		0
17	Long-Chain Omega-3 Polyunsaturated Fatty Acids Modulate Mammary Gland Composition and Inflammation. <i>Journal of Mammary Gland Biology and Neoplasia</i> , 2018, 23, 43-58.	1.0	10
18	Dietary omega-3 and omega-6 polyunsaturated fatty acids modulate hepatic pathology. <i>Journal of Nutritional Biochemistry</i> , 2018, 52, 92-102.	1.9	41

#	ARTICLE	IF	CITATIONS
19	Role of the EHD Family of Endocytic Recycling Regulators for TCR Recycling and T Cell Function. <i>Journal of Immunology</i> , 2018, 200, 483-499.	0.4	13
20	Immune regulation and anti-cancer activity by lipid inflammatory mediators. <i>International Immunopharmacology</i> , 2018, 65, 580-592.	1.7	29
21	Long-chain omega-3 polyunsaturated fatty acids decrease mammary tumor growth, multiorgan metastasis and enhance survival. <i>Clinical and Experimental Metastasis</i> , 2018, 35, 797-818.	1.7	32
22	Macrophage-Derived Neuropilin-2 Exhibits Novel Tumor-Promoting Functions. <i>Cancer Research</i> , 2018, 78, 5600-5617.	0.4	72
23	Abstract 5714: SPADE identification of novel MDSC subsets. , 2018, , .		0
24	Tumor Immuno-Environment in Cancer Progression and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 1-18.	0.8	31
25	Lipid Inflammatory Mediators in Cancer Progression and Therapy. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1036, 145-156.	0.8	6
26	Multifaceted Role of Neuropilins in the Immune System: Potential Targets for Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1228.	2.2	165
27	Abstract LB-192: Phenotyping human myeloid derived suppressor cells (MDSC) subsets. , 2017, , .		4
28	Abstract 245: Dietary long-chain omega-3 fatty acids reduce adipose inflammation in mammary tissue of mice fed moderate fat-isocaloric diets. , 2017, , .		0
29	Genetically Engineered Multivalent Proteins for Targeted Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 3419-3421.	3.2	3
30	Editorial: Improving the data reproducibility and general interest of natural product submissions. <i>International Immunopharmacology</i> , 2016, 37, 3-4.	1.7	2
31	Introduction: Natural product-based drug discovery in Immunopharmacology. <i>International Immunopharmacology</i> , 2016, 37, 1-2.	1.7	3
32	Natural product derived immune-regulatory agents. <i>International Immunopharmacology</i> , 2016, 37, 5-15.	1.7	16
33	Controversies in Neoplastic Myeloplasia. <i>SpringerBriefs in Immunology</i> , 2016, , 1-24.	0.1	0
34	Abstract 4323: Dietary omega-3 suppress mammary tumor growth, metastasis and enhances survival in an iso-caloric pair-fed mice model. , 2016, , .		0
35	Abstract 4312: Preneoplastic activity of dietary poly unsaturated fatty acid (PUFA) regulation of organ and tissue microenvironments in an iso-caloric pair-fed mouse model. , 2016, , .		0
36	Abstract 5144: Role of Neuropilin-2 in the maintenance of tumor associated macrophages. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
37	Myeloid-derived suppressor cells: their role in the pathophysiology of hematologic malignancies and potential as therapeutic targets. <i>Leukemia and Lymphoma</i> , 2015, 56, 2251-2263.	0.6	29
38	Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer. <i>Clinical and Experimental Metastasis</i> , 2015, 32, 111-124.	1.7	17
39	Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy. <i>Oncotarget</i> , 2015, 6, 10498-10509.	0.8	22
40	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
41	Preface: Natural Killer Cells in Cancer: Surveillance, Progression, and Therapy. <i>Critical Reviews in Oncogenesis</i> , 2014, 19, vii-viii.	0.2	0
42	Alternative approaches in the closed system manufacturing for dendritic cell vaccines. <i>Cytotherapy</i> , 2014, 16, S28.	0.3	0
43	Dendritic Cells Transfected with Adenoviral Vectors as Vaccines. <i>Methods in Molecular Biology</i> , 2014, 1139, 97-118.	0.4	3
44	Gene Therapy in Oncology. , 2014, , 493-507.e4.		1
45	Abstract 1167: Osteolysis, splenic and hepatic extramedullary hematopoiesis, MDSCs, tumor growth, and metastases by orthotopic mammary tumors are increased by alcohol consumption and fatty diets. , 2014, , .		0
46	History of myeloid-derived suppressor cells. <i>Nature Reviews Cancer</i> , 2013, 13, 739-752.	12.8	974
47	High fat and alcoholic diets increase hepatic EMH, osteolysis and spontaneous metastases by orthotopic mammary tumors. , 2013, 1, P258.		0
48	Abstract 4979: Multidimensional crosstalk regulates myeloid cell hyperplasia, immune escape, and tumor progression.. , 2013, , .		0
49	Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma. <i>Blood</i> , 2013, 122, 1808-1808.	0.6	0
50	Cryopreservation of adenovirus-transfected dendritic cells (DCs) for clinical use. <i>International Immunopharmacology</i> , 2012, 13, 61-68.	1.7	10
51	Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. <i>International Immunopharmacology</i> , 2012, 13, 245-256.	1.7	35
52	Development and application of site-specific proteomic approach for study protein S-nitrosylation. <i>Amino Acids</i> , 2012, 42, 1541-1551.	1.2	9
53	Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 164-164.	0.8	1
54	Abstract 4363: Tumor regulation of myeloid-derived suppressor cell proliferation, circulation and apoptosis.. , 2012, , .		0

#	ARTICLE	IF	CITATIONS
55	Preface. International Immunopharmacology, 2011, 11, 293-294.	1.7	1
56	Tumor- and organ-dependent infiltration by myeloid-derived suppressor cells. International Immunopharmacology, 2011, 11, 816-826.	1.7	70
57	Immune cell infiltration of primary and metastatic lesions: Mechanisms and clinical impact. Seminars in Cancer Biology, 2011, 21, 131-138.	4.3	64
58	C6 Immunostimulants in cancer therapy. , 2011, , 373-410.		0
59	Bioluminescence in drug development for cancer: Shedding light on therapeutic efficacy. Cancer Biology and Therapy, 2011, 11, 846-848.	1.5	3
60	Immunotherapy of advanced melanoma by intratumoral injections of autologous, purified dendritic cells transduced with gene construct of interleukin-12, with dose-dependent expression under the control of an oral activator ligand.. Journal of Clinical Oncology, 2011, 29, 2540-2540.	0.8	7
61	Abstract 453: Myeloid regulatory cells in cancer patients. , 2011, , .		0
62	Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunology, Immunotherapy, 2010, 59, 47-62.	2.0	46
63	Therapeutic activity of sunitinib for Her2/neu induced mammary cancer in FVB mice. International Immunopharmacology, 2010, 10, 140-145.	1.7	24
64	AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective. Cancer Research, 2010, 70, 5649-5669.	0.4	956
65	Models of Metastasis in Drug Discovery. Methods in Molecular Biology, 2010, 602, 215-233.	0.4	12
66	Abstract B52: Characterizing the MDSCs phenotypes, expansion, and trafficking pattern and associated tumor-induced immune dysfunction. , 2010, , .		0
67	Tumor and iatrogenic regulation of myeloid precursors and their potential to limit immune therapy. Immunotherapy, 2009, 1, 5-9.	1.0	0
68	Cancer-induced Expansion and Activation of CD11b+Gr-1+ Cells Predispose Mice to Adenoviral-triggered Anaphylactoid-type Reactions. Molecular Therapy, 2009, 17, 508-515.	3.7	18
69	Improving the efficacy of cancer immunotherapy. European Journal of Cancer, 2009, 45, 1424-1431.	1.3	50
70	Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. International Immunopharmacology, 2009, 9, 937-948.	1.7	91
71	Autologous dendritic cell vaccine directed at wild type p53 in patients with high-risk breast cancer treated with adjuvant chemotherapy.. , 2009, , .		0
72	Lymphocyte subset recovery following allogeneic bone marrow transplantation: CD4+-cell count and transplant-related mortality. Bone Marrow Transplantation, 2008, 41, 19-21.	1.3	6

#	ARTICLE	IF	CITATIONS
73	Closing the manufacturing process of dendritic cell vaccines transduced with adenovirus vectors. <i>International Immunopharmacology</i> , 2008, 8, 1728-1736.	1.7	19
74	Amyloid Precursor-Like Protein 2 Increases the Endocytosis, Instability, and Turnover of the H2-Kd MHC Class I Molecule. <i>Journal of Immunology</i> , 2008, 181, 1978-1987.	0.4	44
75	Follistatin as an Inhibitor of Experimental Metastasis. <i>Clinical Cancer Research</i> , 2008, 14, 624-626.	3.2	10
76	Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. <i>Blood</i> , 2008, 111, 5457-5466.	0.6	326
77	The evolution of diversity within tumors and metastases. , 2008, , 59-90.		5
78	Significant Expansion of Myeloid Derived Suppressor Cells in Patients with High- Risk Breast Cancer Treated with Dose Dense Adjuvant Chemotherapy. <i>Blood</i> , 2008, 112, 4653-4653.	0.6	0
79	Clonal Selection of Metastasis within the Life History of a Tumor. <i>Cancer Research</i> , 2007, 67, 11471-11475.	0.4	112
80	Flt3 Ligand Delivered in a Pluronic Formulation Prolongs the Survival of Mice with Orthotopic Pancreatic Adenocarcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007, 22, 235-238.	0.7	5
81	Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy. <i>Clinical Cancer Research</i> , 2007, 13, 5243-5248.	3.2	243
82	CCL21 Is an effective surgical neoadjuvant for treatment of mammary tumors. <i>Cancer Biology and Therapy</i> , 2007, 6, 1217-1221.	1.5	13
83	112: Rigorous protocols using Alemtuzumab to T cell deplete stem cell products. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 43-44.	2.0	1
84	228: Nonmyeloablative allogeneic stem cell transplantation (NST) for hematologic malignancies (HM) using pentostatin/low-dose total body irradiation (Pt-TBI). <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 83-84.	2.0	12
85	Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer. <i>American Journal of Pathology</i> , 2007, 170, 793-804.	1.9	419
86	Chemoprevention by cyclooxygenase-2 inhibition reduces immature myeloid suppressor cell expansion. <i>International Immunopharmacology</i> , 2007, 7, 140-151.	1.7	123
87	CCL21-induced immune cell infiltration. <i>International Immunopharmacology</i> , 2007, 7, 272-276.	1.7	11
88	Immune reconstitution after autologous hematopoietic transplantation with Lin ^{hi} , CD34 ⁺ , Thy-1 ^{lo} selected or intact stem cell products. <i>International Immunopharmacology</i> , 2007, 7, 1033-1043.	1.7	5
89	Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection. <i>Cancer Gene Therapy</i> , 2007, 14, 364-371.	2.2	36
90	Inflammatory cell infiltration of tumors: Jekyll or Hyde. <i>Cancer and Metastasis Reviews</i> , 2007, 26, 373-400.	2.7	283

#	ARTICLE	IF	CITATIONS
91	Inhibition of intestinal cancer by VPS extract of the <i>Coriolus versicolor</i> mushroom in C57BL/6J Δ Apc ^{Min} mice.. <i>FASEB Journal</i> , 2007, 21, A756.	0.2	0
92	Effect of T Cell Recovery on Overall Survival (OS) Following Pentostatin Conditioning for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).. <i>Blood</i> , 2007, 110, 2994-2994.	0.6	0
93	Editorial. <i>International Immunopharmacology</i> , 2006, 6, 1039.	1.7	1
94	New standards for manuscripts on natural products. <i>International Immunopharmacology</i> , 2006, 6, 1223.	1.7	1
95	Targeted nanoparticles for detecting and treating cancer. <i>Drug Development Research</i> , 2006, 67, 70-93.	1.4	202
96	Differential T Cell Suppression by Two Different Pentostatin Conditioning Protocols for Nonmyeloablative Allogeneic Stem Cell Transplantation (NST).. <i>Blood</i> , 2006, 108, 5373-5373.	0.6	0
97	Mechanism of Alemtuzumab Depletion of T Cells in Stem Cell Products.. <i>Blood</i> , 2006, 108, 5176-5176.	0.6	0
98	Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. <i>International Journal of Pharmaceutics</i> , 2005, 293, 281-290.	2.6	133
99	Murine mammary adenocarcinoma cells transfected with p53 and/or Flt3L induce antitumor immune responses. <i>Cancer Gene Therapy</i> , 2005, 12, 427-437.	2.2	12
100	Down-Regulation of Vascular Endothelial Cell Growth Factor-C Expression Using Small Interfering RNA Vectors in Mammary Tumors Inhibits Tumor Lymphangiogenesis and Spontaneous Metastasis and Enhances Survival. <i>Cancer Research</i> , 2005, 65, 9004-9011.	0.4	133
101	Hematopoietic Progenitor Cell Mobilization in Mice by Sustained Delivery of Granulocyte Colony-Stimulating Factor. <i>Journal of Interferon and Cytokine Research</i> , 2005, 25, 490-500.	0.5	8
102	Treatment with Flt3 ligand plasmid reverses allergic airway inflammation in ovalbumin-sensitized and -challenged mice. <i>International Immunopharmacology</i> , 2005, 5, 345-357.	1.7	14
103	Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) for Hematologic Malignancies (HM) Using Pentostatin/Low-Dose Total Body Irradiation (TBI).. <i>Blood</i> , 2005, 106, 3671-3671.	0.6	0
104	Flt-3 Ligand Reverses Late Allergic Response and Airway Hyper-Responsiveness in a Mouse Model of Allergic Inflammation. <i>Journal of Immunology</i> , 2004, 172, 5016-5023.	0.4	66
105	Fractionation of Aloe vera L. inner gel, purification and molecular profiling of activity. <i>International Immunopharmacology</i> , 2004, 4, 1757-1773.	1.7	110
106	Donor immune reconstitution after liver+small bowel transplantation for multiple intestinal atresia with immunodeficiency. <i>Blood</i> , 2004, 103, 1171-1174.	0.6	59
107	Intratumoral, Injection of Adenoviral Flt3 Ligand Has Therapeutic Activity in Association with Increased Intratumoral Levels of T Cells but Not Dendritic Cells.. <i>Blood</i> , 2004, 104, 5280-5280.	0.6	0
108	Use of Matrix Metalloproteinase (MMP)-9 Knockout Mice Demonstrates that MMP-9 Activity Is not Absolutely Required for G-CSF or Flt-3 Ligand-Induced Hematopoietic Progenitor Cell Mobilization or Engraftment. <i>Stem Cells</i> , 2003, 21, 417-427.	1.4	36

#	ARTICLE	IF	CITATIONS
109	Effect of Granulocyte Colony-Stimulating Factor on Bone Metabolism During Peripheral Blood Stem Cell Mobilization. <i>International Journal of Hematology</i> , 2003, 77, 75-81.	0.7	16
110	Regional, but not systemic recruitment/expansion of dendritic cells by a pluronic-formulated Flt3-ligand plasmid with vaccine adjuvant activity. <i>Vaccine</i> , 2003, 21, 3019-3029.	1.7	24
111	Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy. <i>International Immunopharmacology</i> , 2003, 3, 1121-1143.	1.7	29
112	Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation ¹ . <i>Transplantation</i> , 2003, 76, 877-881.	0.5	18
113	Biotherapeutics. , 2003, , 281-324.		0
114	Therapeutic resolution of late allergic response and airway hyperresponsiveness by Flt-3 ligand in a mouse model of allergic inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S24-S24.	1.5	0
115	Flt3-ligand: A novel immunomodulator in the treatment of bronchial asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, S39-S39.	1.5	0
116	Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells. <i>International Immunopharmacology</i> , 2002, 2, 925-940.	1.7	10
117	Flt3 ligand and conjugation to IL-1 β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine. <i>Vaccine</i> , 2002, 20, 2358-2368.	1.7	14
118	Monocyte/macrophage recruitment, activation and differentiation modulate interleukin-8 production: a paracrine role of tumor-associated macrophages in tumor angiogenesis. <i>In Vivo</i> , 2002, 16, 471-7.	0.6	49
119	Activation-induced T cell apoptosis by monocytes from stem cell products. <i>International Immunopharmacology</i> , 2001, 1, 1307-1319.	1.7	15
120	Flt3 ligand: a novel cytokine prevents allergic asthma in a mouse model. <i>International Immunopharmacology</i> , 2001, 1, 2081-2089.	1.7	25
121	Ex vivo purging by adenoviral p53 gene therapy does not affect NOD-SCID repopulating activity of human CD34+ cells. <i>Cancer Gene Therapy</i> , 2001, 8, 936-947.	2.2	7
122	Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. <i>Experimental Hematology</i> , 2001, 29, 1185-1193.	0.2	64
123	Editorial. <i>International Journal of Immunopharmacology</i> , 2000, 22, 479-482.	1.1	0
124	Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. <i>International Journal of Immunopharmacology</i> , 2000, 22, 865-876.	1.1	21
125	Mechanisms of immune dysfunction in stem cell transplantation. <i>International Journal of Immunopharmacology</i> , 2000, 22, 1041-1056.	1.1	9
126	Editorial. <i>International Journal of Immunopharmacology</i> , 2000, 22, iii-iv.	1.1	0

#	ARTICLE	IF	CITATIONS
127	Purging of human breast cancer cells from stem cell products with an adenovirus containing p53. <i>Cancer Gene Therapy</i> , 2000, 7, 197-206.	2.2	12
128	Immune dysfunction despite high levels of immunoregulatory cytokine gene expression in autologous peripheral blood stem cell transplanted non-Hodgkin's lymphoma patients. <i>Experimental Hematology</i> , 2000, 28, 499-507.	0.2	28
129	Comparison of the Hematopoietic Activity of flt-3 Ligand and Granulocyte-Macrophage Colony-Stimulating Factor Acting Alone or in Combination. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 711-720.	1.8	23
130	Activity of Acetyl-Ser-Asp-Lys-Pro (AcSDKP) on Human Hematopoietic Progenitor Cells in Short-Term and Long-Term Bone Marrow Cultures. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 489-496.	1.8	8
131	Growth Factor Mobilization and Modulation of Progenitor Cell Adhesion to Stromal Cells: Role of VLA-4. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 507-515.	1.8	6
132	Expression of Interleukin-10 in Isolated CD8+ T Cells and Monocytes from Growth Factor-Mobilized Peripheral Blood Stem Cell Products: A Mechanism of Immune Dysfunction. <i>Journal of Interferon and Cytokine Research</i> , 1999, 19, 351-360.	0.5	16
133	Positive Interaction between 5-FU and FdUMP[10] in the Inhibition of Human Colorectal Tumor Cell Proliferation. <i>Oligonucleotides</i> , 1999, 9, 481-486.	4.4	18
134	Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2. <i>International Journal of Immunopharmacology</i> , 1999, 21, 509-521.	1.1	3
135	N-linked oligosaccharides and metastatic propensity in in vivo selected mouse mammary adenocarcinoma cells. <i>Clinical and Experimental Metastasis</i> , 1999, 17, 437-444.	1.7	4
136	Increased Cytotoxicity and Decreased In Vivo Toxicity of FdUMP[10] Relative to 5-FU. <i>Nucleosides & Nucleotides</i> , 1999, 18, 1789-1802.	0.5	19
137	Pharmacodynamic aspects of peptide administration biological response modifiers. <i>Advanced Drug Delivery Reviews</i> , 1998, 33, 241-252.	6.6	46
138	Enhancement of Adenovirus-Mediated Gene Transfer to Human Bone Marrow Cells. <i>Leukemia and Lymphoma</i> , 1998, 29, 439-451.	0.6	13
139	IL-2 Expansion of T and NK Cells from Growth Factor-Mobilized Peripheral Blood Stem Cell Products. <i>Journal of Immunotherapy</i> , 1998, 21, 409-417.	1.2	9
140	Monocytes from mobilized stem cells inhibit T cell function. <i>Journal of Leukocyte Biology</i> , 1997, 61, 583-591.	1.5	51
141	Studies on optimal dose and administration schedule of a hematopoietic stimulatory \hat{I}^2 -(1,4)-linked mannan. <i>International Journal of Immunopharmacology</i> , 1996, 18, 113-126.	1.1	22
142	In vivo haemoprotective activity of tetrapeptide AcSDKP combined with granulocyte colony stimulating factor following sublethal irradiation. <i>British Journal of Haematology</i> , 1996, 94, 619-627.	1.2	12
143	Differential recovery of polymorphonuclear neutrophils, B and T cell subpopulations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 1994, 39, 59-67.	2.0	15
144	Clinical outcome of peripheral blood stem cell support. <i>Medical Oncology</i> , 1994, 11, 43-46.	1.2	11

#	ARTICLE	IF	CITATIONS
145	Molecular pharmacology of the beta-adrenergic receptor on THP-1 cells. <i>International Journal of Immunopharmacology</i> , 1993, 15, 219-228.	1.1	36
146	The pharmaceuticals and delivery of therapeutic polypeptides and proteins. <i>Advanced Drug Delivery Reviews</i> , 1993, 10, 247-299.	6.6	62
147	Antitumor response to recombinant murine interferon γ correlates with enhanced immune function of organ-associated, but not recirculating cytolytic T lymphocytes and macrophages. <i>Cancer Immunology, Immunotherapy</i> , 1993, 37, 299-306.	2.0	11
148	T-Cell Reconstitution by Molecular, Phenotypic, and Functional Analysis in the Thymus, Bone Marrow, Spleen, and Blood Following Split-Dose Polychemotherapy and Therapeutic Activity for Metastatic Breast Cancer in Mice. <i>Journal of Immunotherapy</i> , 1993, 14, 258-268.	1.2	15
149	Effect of tumor burden and route of administration on the immunotherapeutic properties of polyinosinic-polycytidylic acid stabilized with poly-L-lysine in carboxymethyl cellulose [Poly(I,C)-LC]. <i>International Journal of Immunopharmacology</i> , 1992, 14, 1341-1353.	1.1	14
150	Deoxyspergualin, a novel immunosuppressant, markedly inhibits human mixed lymphocyte reaction and cytotoxic T-lymphocyte activity in vitro. <i>International Journal of Immunopharmacology</i> , 1992, 14, 731-737.	1.1	31
151	Synergy in the toxicity of cytokines: Preclinical studies. <i>International Journal of Immunopharmacology</i> , 1992, 14, 383-390.	1.1	3
152	The rational development of biological response modifiers. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1992, 4, 177-178.	0.7	0
153	Development of immunotherapeutic strategies for the treatment of malignant neoplasms. <i>Biotherapy (Dordrecht, Netherlands)</i> , 1992, 4, 215-236.	0.7	9
154	Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspirane, SK&F 105685. <i>International Journal of Immunopharmacology</i> , 1991, 13, 91-100.	1.1	10
155	Effects of bestatin on myelopoietic stem cells in normal and cyclophosphamide-treated mice. <i>Cancer Immunology, Immunotherapy</i> , 1990, 32, 75-80.	2.0	13
156	Induction of non-specific suppressor cells in normal lewis rats by a novel azaspirane SK&F 105685. <i>Journal of Autoimmunity</i> , 1990, 3, 485-500.	3.0	28
157	Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes. <i>International Journal of Immunopharmacology</i> , 1989, 11, 839-846.	1.1	23
158	Therapeutic and Toxic Activity of Tumor Necrosis Factor Is Synergistic with Gamma Interferon. <i>Pathology and Immunopathology Research</i> , 1989, 8, 21-34.	0.8	14
159	Development of Immunotherapeutic Strategies for the Treatment of Malignant Neoplasia. <i>Pathology and Immunopathology Research</i> , 1989, 8, 250-275.	0.8	2
160	Therapeutic Potential of Cytokines: A Comparison of Preclinical and Clinical Studies. <i>Progress in Tumor Research</i> , 1988, 32, 154-173.	0.1	14
161	Correlation of immunomodulatory and therapeutic activities of interferon and interferon inducers in metastatic disease. <i>Journal of Cellular Biochemistry</i> , 1988, 36, 377-392.	1.2	9
162	A novel method for selection of invasive tumor cells: Derivation and characterization of highly metastatic K1735 melanoma cell lines based on in vitro and in vivo invasive capacity. <i>Clinical and Experimental Metastasis</i> , 1988, 6, 301-318.	1.7	24

#	ARTICLE	IF	CITATIONS
163	Immunotherapy of Metastatic Disease. <i>Seminars in Thrombosis and Hemostasis</i> , 1988, 14, 79-87.	1.5	3
164	Therapeutic Potential of Cytokines. <i>Advances in Experimental Medicine and Biology</i> , 1988, 233, 395-403.	0.8	0
165	Toxicity of Polyinosinic-Polycytidylic Acid Admixed with Poly-L-Lysine and Solubilized with Carboxymethylcellulose in Mice. <i>Pathology and Immunopathology Research</i> , 1987, 6, 37-50.	0.8	16
166	Immunomodulatory and therapeutic properties of alkyl lysophospholipids in mice. <i>Lipids</i> , 1987, 22, 871-877.	0.7	24
167	Comparison of Therapeutic Potential of Cytokines. , 1987, , 483-490.		0
168	Biological response modifiers: realizing their potential in cancer therapeutics. <i>Trends in Pharmacological Sciences</i> , 1986, 7, 277-281.	4.0	8
169	Proliferation of human peripheral blood lymphocytes induced by recombinant human interleukin 2: Contribution of large granular lymphocytes and T lymphocytes. <i>Cellular Immunology</i> , 1986, 102, 261-272.	1.4	42
170	Tumor models and approaches to the development of optimal therapeutic protocols. <i>International Journal of Immunopharmacology</i> , 1985, 7, 408.	1.1	0
171	Relationship of macrophage content, immunogenicity, and metastatic potential of a murine osteosarcoma of recent origin. <i>Clinical and Experimental Metastasis</i> , 1985, 3, 61-72.	1.7	2
172	Immunotherapeutic agents: Their role in cellular immunity and their therapeutic potential. <i>Seminars in Immunopathology</i> , 1985, 8, 327-346.	4.0	10
173	Comparison of immunomodulatory and immunotherapeutic properties of biologic response modifiers. <i>Seminars in Immunopathology</i> , 1985, 8, 429-443.	4.0	9
174	The effect of experimental conditions on the assessment of T cell immunomodulation by biological response modifiers (thymosin fraction five). <i>Immunopharmacology</i> , 1984, 7, 17-26.	2.0	16
175	Lymphokines, monoclonal antibodies, and other biological response modifiers in the treatment of cancer. <i>Cancer</i> , 1984, 54, 2795-2806.	2.0	43
176	The selective nature of metastasis. <i>Cancer and Metastasis Reviews</i> , 1983, 2, 25-40.	2.7	34
177	In vitro characteristics of metastatic variant subclones of restricted genetic origin. <i>Journal of Supramolecular Structure and Cellular Biochemistry</i> , 1981, 15, 139-151.	1.4	30
178	Role of NK cells in tumour growth and metastasis in beige mice. <i>Nature</i> , 1980, 284, 622-624.	13.7	538
179	Introduction of metastatic heterogeneity by short-term in vivo passage of a cloned transformed cell line. <i>Journal of Supramolecular Structure</i> , 1979, 12, 227-243.	2.3	47
180	CCL21 induces extensive intratumoral immune cell infiltration and specific anti-tumor cellular immunity. <i>International Journal of Oncology</i> , 0, , .	1.4	22